Rodger Novak Sells 75,795 Shares of Crispr Theraptc (CRSP) Stock
Crispr Theraptc (NASDAQ:CRSP) CEO Rodger Novak sold 75,795 shares of the business’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $20.25, for a total transaction of $1,534,848.75. Following the sale, the chief executive officer now owns 1,232,697 shares in the company, valued at $24,962,114.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Rodger Novak also recently made the following trade(s):
- On Thursday, June 22nd, Rodger Novak sold 10,825 shares of Crispr Theraptc stock. The stock was sold at an average price of $15.37, for a total transaction of $166,380.25.
- On Wednesday, June 21st, Rodger Novak sold 30,222 shares of Crispr Theraptc stock. The stock was sold at an average price of $15.01, for a total transaction of $453,632.22.
- On Friday, June 9th, Rodger Novak sold 5,303 shares of Crispr Theraptc stock. The stock was sold at an average price of $15.02, for a total transaction of $79,651.06.
Crispr Theraptc (NASDAQ CRSP) traded up 4.13% during mid-day trading on Wednesday, hitting $20.66. 344,014 shares of the company were exchanged. The firm has a 50 day moving average price of $17.74 and a 200 day moving average price of $17.59. The stock’s market cap is $838.61 million. Crispr Theraptc has a 12 month low of $11.63 and a 12 month high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.62) by $0.06. The company had revenue of $3.60 million during the quarter, compared to the consensus estimate of $3.29 million. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company’s revenue for the quarter was up 350.0% on a year-over-year basis. Analysts anticipate that Crispr Theraptc will post ($2.43) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2017/08/30/rodger-novak-sells-75795-shares-of-crispr-theraptc-crsp-stock.html.
Several hedge funds have recently added to or reduced their stakes in CRSP. ARK Investment Management LLC acquired a new stake in shares of Crispr Theraptc during the second quarter valued at $206,000. Vanguard Group Inc. acquired a new stake in shares of Crispr Theraptc during the second quarter valued at $273,000. Wells Fargo & Company MN increased its stake in shares of Crispr Theraptc by 459.7% in the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after buying an additional 6,560 shares during the last quarter. IHT Wealth Management LLC acquired a new stake in shares of Crispr Theraptc during the first quarter valued at $110,000. Finally, Credit Suisse AG acquired a new stake in shares of Crispr Theraptc during the first quarter valued at $1,742,000. Institutional investors own 23.90% of the company’s stock.
CRSP has been the topic of a number of recent research reports. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research note on Tuesday, July 18th. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a research note on Thursday, July 13th. They set a “hold” rating and a $16.00 price target on the stock. Chardan Capital reiterated a “buy” rating on shares of Crispr Theraptc in a research note on Monday, August 14th. Finally, Cann initiated coverage on shares of Crispr Theraptc in a research note on Monday, July 17th. They set a “market perform” rating on the stock. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. Crispr Theraptc has a consensus rating of “Buy” and an average price target of $21.92.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Stock Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related stocks with our FREE daily email newsletter.